Dysregulation in NLRP3 and NLRP6 inflammasomes, and consequently in IL-1 β and IL-18, can lead to NASH, which enables gut dysbiosis occurrence and portal circulation homeostasis disruption [16]. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.